📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-14 17:11
0 analysed today
FollowTelegram
0
Today
152,077
All-time analysed
43,619
Positive
6,746
Negative
92,865
Neutral
8,779
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Onyx Biotec: Offer Opening Public Announcement Cum Corrigendum Issued for Open Offer
VC Corporate Advisors Private Limited has issued an Offer Opening Public Announcement cum Corrigendum to the Detailed Public Statement for the public shareholders of Onyx Biotec Limited. The filing relates to the formal commencement and schedule of an open offer process for the company. Specific offer details such as share price, offer size, and post-transaction shareholding are referenced in the statutory advertisement, while the attachment text primarily contains legal transfer and duplicate share certificate loss notices. As of Mar 2026, the promoter holding stood at 65.1%, with TTM revenue of ₹131 Cr.
Confidence: MEDIUM
What changedFormal opening announcement and corrigendum issued for the open offer to public shareholders.
Why it mattersOpen offers can result in a change in control, management shift, or substantial acquisition of voting rights for the target company.
Notice claim window: 7 daysPromoter Holding: 65.1%TTM Revenue: ₹131 Cr
📅 Short termMarket pricing of the stock will likely anchor around the specified open offer price during the tendering window.
📈 Long termAny change of control or new strategic investor could influence strategic direction, capital allocation, and planned facility expansions.
⚠ Risk flags
- Under-subscription or over-subscription dynamics during the open offer period
- Potential changes to control or management alignment
Key Highlights
Manager to the offer, VC Corporate Advisors Private Limited, issued the offer opening announcement cum corrigendum.
The transaction impacts target company Onyx Biotec Limited, which generated TTM revenue of ₹131 Cr and TTM PAT of ₹5 Cr.
Promoter holding stood at 65.1% prior to the offer as of March 2026 filings.
The document submission includes a notice for claims within 7 days regarding duplicate share requests.
👀 What to Watch
Shareholders should review the Detailed Public Statement and Letter of Offer for the open offer price, tendering dates, and acquirer identity to decide on tendering.
Onyx Biotec Discloses IDC Recommendation on Open Offer to Acquire 26% Stake (47.14 Lakh Shares)
Onyx Biotec Limited submitted newspaper publications of the Independent Director Committee (IDC) recommendations concerning an open offer to acquire up to 47,14,372 equity shares. The offer covers 26.00% of the total paid-up voting equity share capital. The acquirers are Mr. Kunal Bhardwaj, Mr. Gautam Bhardwaj, Mr. Kanhaiya Bhardwaj, and Mr. Kapil Bhardwaj. The recommendation dated October 07, 2026, was published in newspapers on October 08, 2026, pursuant to SEBI (SAST) Regulations, 2011.
Confidence: HIGH
What changedThe company has formally submitted newspaper advertisements containing the Independent Director Committee's recommendations on an ongoing 26% open offer.
Why it mattersA 26% share acquisition triggers substantial changes in voting power and potential management influence, impacting control alongside the existing 65.1% promoter holding.
Shares to be acquired: 47,14,372Voting capital under offer: 26.00%Offer share face value: Rs. 10 /-IDC Recommendation date: October 07, 2026
📅 Short termPublic shareholders will monitor the pricing fairness evaluated by the IDC and assess whether to tender their shares during the upcoming tendering window.
📈 Long termDepending on the acceptance rate, this acquisition may alter the shareholding structure and corporate governance dynamic at the board level.
⚠ Risk flags
- Potential change in control or activist accumulation
- Post-offer shareholding realignment
Key Highlights
Open offer made to public shareholders to acquire up to 47,14,372 equity shares of face value Rs 10 each
Shares under offer represent 26.00% of the company's total paid-up equity and voting capital
Committee of Independent Directors (IDC) issued its recommendation dated October 07, 2026
Acquisition proposed collectively by four acquirers: Kunal Bhardwaj, Gautam Bhardwaj, Kanhaiya Bhardwaj, and Kapil Bhardwaj
👀 What to Watch
Track the detailed offer price and independent directors' specific stance in the published IDC recommendation, along with the tender offer opening and closing timeline under SEBI (SAST) norms.
Onyx Biotec Independent Directors Review 26.00% Open Offer for 47.14 Lakh Shares
The Committee of Independent Directors of Onyx Biotec met on October 07, 2026, to review and analyze an Open Offer under SEBI SAST Regulations. The offer is made by Mr. Kunal Bhardwaj, Mr. Gautam Bhardwaj, Mr. Kanhaiya Bhardwaj, and Mr. Kapil Bhardwaj to acquire up to 47,14,372 equity shares. This represents 26.00% of the company's total voting capital. The Committee's detailed recommendations will be published in newspapers following the Detailed Public Statement dated July 31, 2026.
Confidence: HIGH
What changedThe Independent Directors have formally met to review the terms of the takeover open offer for a 26% stake in Onyx Biotec.
Why it mattersA 26% acquisition can alter ownership structure, board influence, or control dynamics for Onyx Biotec, which had a 65.1% promoter holding as of March 2026.
Shares to acquire: 47,14,372Voting capital percentage: 26.00%Face value per share: Rs. 10/-Meeting date: October 07, 2026
📅 Short termInvestors will look for the official recommendation disclosure detailing whether the Independent Directors consider the offer price fair and reasonable.
📈 Long termDepending on final tender acceptance, the acquirers could become substantial shareholders, potentially driving operational or strategic shifts in the business.
⚠ Risk flags
- Offer price was not disclosed in the filing extract
- Potential change in management influence or shareholding dilution depending on tendering
Key Highlights
Open offer involves acquisition of up to 47,14,372 equity shares of face value Rs 10 each
Target shares represent 26.00% of total paid-up equity and voting capital
Committee of Independent Directors met on October 07, 2026, to review the offer terms
Detailed recommendations to follow publication aligned with the July 31, 2026 Detailed Public Statement
👀 What to Watch
Track the upcoming newspaper publication of the Independent Directors' formal recommendation and offer price details to evaluate the acquirers' offer against the market valuation.
Onyx Biotec Faces Open Offer of ₹17.21 Cr for 26% Stake at ₹36.50/Share by Acquirers
Four individual acquirers (Kunal, Gautam, Kanhaiya, and Kapil Bhardwaj) have issued a Letter of Offer to acquire up to 47,14,372 equity shares representing 26.00% of Onyx Biotec Limited. The open offer is priced at ₹36.50 per share payable in cash, amounting to a total offer size of approximately ₹17.21 crore. The transaction is triggered under SEBI (SAST) Regulations 3(1) and 4 for substantial share acquisition accompanied by a change in control and management. The tendering period opens on October 13, 2026, and closes on October 27, 2026.
Confidence: HIGH
What changedAcquirers have submitted the formal Letter of Offer to public shareholders for acquiring a 26% stake with an accompanying change in control.
Why it mattersA change in control and management could lead to strategic realignments, changes in operational priorities, and potential board restructuring for Onyx Biotec.
Offer Price per Share: Rs. 36.50Shares to be Acquired: 47,14,372Percentage of Capital: 26.00%Offer Size: ₹17.21 CrMarketable Lot: 2000 equity shares
📅 Short termPublic shareholders have an exit option at ₹36.50 per share during the tendering window opening October 13, 2026, ending October 27, 2026.
📈 Long termIf successfully concluded, the induction of new management could alter operational strategy, execution on facility upgrades, and financial governance.
⚠ Risk flags
- Uncertainty regarding operational direction under new management
- Risk of low tender acceptance or delays if regulatory objections arise
Key Highlights
Open offer for up to 47,14,372 equity shares representing 26.00% voting share capital
Offer price fixed at ₹36.50 per equity share in cash
Total open offer value stands at approximately ₹17.21 crore
Tendering window runs from October 13, 2026, to October 27, 2026
Triggered under Regulations 3(1) & 4 of SEBI (SAST) Regulations for change in control and management
👀 What to Watch
Investors should watch the tendering period from October 13 to October 27, 2026, and monitor subsequent disclosures on post-offer shareholding and incoming management plans.
Open Offer for 26% Stake at ₹61.00 per Share by Acquirers
A group of individual acquirers (Sanjay Jain, Naresh Kumar, and Promod Kumar) has announced a mandatory open offer to acquire up to 4,815,000 equity shares of Onyx Biotec Limited, representing 26% of the total voting capital. The offer price is set at ₹61.00 per share, implying a total potential cash outlay of ₹29.37 Cr. This offer was triggered by a Share Purchase Agreement (SPA) dated July 24, 2026. The tendering period for shareholders is scheduled to run from September 18, 2026, to October 1, 2026.
Confidence: HIGH
What changedA change in significant shareholding/control is underway as new acquirers have triggered a mandatory open offer to the public shareholders.
Why it mattersThe entry of new major shareholders can lead to changes in management strategy and capital allocation, especially as the company is currently upgrading its manufacturing units for large volume parentals.
Offer Price: ₹61.00Offer Size (Shares): 4,815,000Total Offer Value: ₹29.37 CrOffer Value vs Net Worth: 53.4%Tendering Start Date: September 18, 2026
📅 Short termThe stock price is expected to remain anchored near the ₹61.00 offer price as the market absorbs the terms of the acquisition.
📈 Long termThe long-term impact depends on the new acquirers' ability to execute the planned Unit I and Unit II upgrades and improve the current low ROCE of 1.1%.
⚠ Risk flags
- Management transition risk
- Potential for reduced public float/liquidity post-offer
- Execution risk of the underlying business turnaround
Key Highlights
Open offer to acquire 4,815,000 shares representing 26% of the company's voting capital
Offer price fixed at ₹61.00 per equity share to be paid in cash
Total maximum consideration for the offer is ₹29.37 Cr, which is approximately 53.4% of the company's Net Worth
Tendering period for public shareholders starts on September 18, 2026, and ends on October 1, 2026
The offer is triggered following a Share Purchase Agreement (SPA) dated July 24, 2026
👀 What to Watch
Retail investors should compare the current market price with the ₹61.00 offer price; if the market price is significantly lower, the open offer provides a potential exit route during the September tendering window.
